Publications by authors named "Ram-Wolff C"
Article Synopsis
- - The study investigates primary cutaneous marginal zone lymphoma (PCMZL) by analyzing recurrent cases to determine whether it's a reactive process or a true lymphoma, utilizing data from the French Study Group of Cutaneous Lymphoma (GFELC).
- - Methods included assessing histology, B-cell clonality, and immunophenotype of lesions, revealing that most initial cases were localized, with differences in recurrence times based on location, and certain clonal patterns were more prominent in local recurrences.
- - The findings suggest that assessing immunoglobulin phenotype, particularly IgM and IgD, may be critical for diagnosing PCMZL, as IgM-positive cases tend to lead to more aggressive transformation and poorer prognosis, indicating different biological
Article Synopsis
- Sezary syndrome (SS) used to have very few treatment options and not a good outlook for patients, but new therapies are helping a lot.
- In a study of 178 patients treated from 2012 to 2020, more advanced treatments led to much better survival rates: about 56% of patients lived at least 5 years.
- Patients who had a special treatment called allogeneic stem-cell transplantation (AlloSCT) had even better chances to survive, with around 91% living for 5 years, but those who couldn't get that treatment still faced challenges.
Article Synopsis
- Sézary syndrome is a rare and deadly skin cancer, and this study looked into the survival rates and factors affecting outcomes, particularly focusing on the treatment mogamulizumab.
- *The research analyzed data from 339 patients diagnosed between 2000 and 2020 across Europe, highlighting that age over 80 and large-cell transformation worsened survival rates.
- *Results indicated that patients treated with mogamulizumab had significantly lower mortality rates, suggesting it is an effective treatment option for Sézary syndrome.
Cutaneous T-cell lymphomas (CTCL) are a diverse group of malignant blood disorders characterized by initial skin infiltration, and sometimes, tumor spreading to lymph nodes, blood, and viscera. Mycosis fungoides is the most common form. Sézary syndrome is a distinctive form of CTCL marked by a significant presence of circulating tumor cells in peripheral blood.
View Article and Find Full Text PDFArticle Synopsis
- Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic skin cancers that require various treatment strategies; interferon-α (IFN-α) has been used for years, but only the pegylated form, PEG-IFN-α-2a, remains available, though not officially approved for these conditions.
- A study involving 105 patients across 10 countries assessed the effectiveness and safety of PEG-IFN-α-2a, focusing on the time to next treatment (TTNT) as a measure of its clinical benefit.
- Results showed a 53.3% overall response rate with better TTNT for patients receiving combination therapy (10.4 months) compared
Article Synopsis
- CD39 is an enzyme in a pathway that helps suppress the immune system and is linked to the growth and spread of solid tumors, particularly in skin-related cancers.
- Research found that CD39 is overexpressed in specific T-cell lymphomas, including Sezary syndrome and mycosis fungoides, in both blood and skin lymphocytes.
- The study suggests that blocking the CD39/CD73/adenosine pathway could be a promising approach for treating these types of cutaneous T-cell lymphomas.
Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study examines patterns of clinical care and therapeutic benefit as measured by TTNT.
View Article and Find Full Text PDFBackground: Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T-cell lymphoma (CTCL): Sézary syndrome (SS) or Mycosis Fungoides (MF).
Objectives: The real-world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF).
Methods: In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres.
Background: Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs.
View Article and Find Full Text PDFArticle Synopsis
- PCDLBCL-LT is a type of aggressive skin lymphoma that rarely affects bones, and five cases with bone involvement were documented.
- Four of the cases were identified through advanced imaging (PET/CT) during initial staging, while the fifth case presented after a tibial fracture.
- All patients experienced early relapses after receiving first-line treatment (rituximab and chemotherapy), indicating that bone involvement is linked to a worse prognosis, and alternative imaging methods should be used for better diagnosis.
Background: Our objective was to describe the clinical, histological characteristics, and disease outcome of a cohort of mycosis fungoides (MF) diagnosed during childhood including disease status at adulthood.
Methods: This is a retrospective multicentre survey of patients aged under 18 years at diagnosis with histologically confirmed MF. Patients' clinical and histological characteristics, treatments, and disease outcome (for patients followed for more than 12 months) were analysed.